Prohibits incarcerated individuals who are determined to suffer from a substance use disorder for which there is no FDA approved addiction medications from being administered medication approved for a different disorder.
Impact
The implementation of S08033 could significantly change the landscape of healthcare provided in state correctional facilities. By mandating that only FDA-approved substances for a particular disorder be administered, the bill could improve the overall quality of care provided to inmates and promote more effective and targeted treatment plans. This could lead to better rehabilitation outcomes for individuals suffering from substance use disorders while incarcerated, aligning the treatment protocols in correctional facilities more closely with established medical practices.
Summary
Bill S08033 aims to address the treatment of incarcerated individuals suffering from substance use disorders. Specifically, the bill proposes that inmates diagnosed with a substance use disorder that lacks FDA-approved medications should not receive medications intended for other disorders. This legislative approach seeks to create a more structured treatment program that aligns specifically with recognized standards for substance abuse treatment, as outlined by health authorities and supported by the correction law in New York State.
Contention
However, the bill has the potential to raise concerns regarding the adequacy of treatment for individuals whose substance use disorders do not have FDA-approved medication options. Critics of the effort may argue that such a prohibition could lead to inadequate treatment for some individuals, potentially exacerbating mental health issues and jeopardizing rehabilitation efforts. Additionally, there may be discussions around the ethical implications of denying medication that, while intended for different disorders, could still support the overall health and recovery of these individuals.
Provides standards for correctional facilities in relation to medication assisted treatment for opioid use disorders and the testing for opioid use when an individual is first incarcerated.
Prohibits nursing homes and care facilities that are registered with the state of New York and registered with the federal Drug Enforcement Agency, that maintains a stock of, and directly dispenses, controlled substance medications from denying admission to individuals receiving a controlled substance medication for a substance use disorder.
Prohibits county correction officers from dispensing medications to incarcerated individuals on the premises of a local correctional facility, but corrections officers or staff may dispense or administer medications used for the emergency treatment of known or suspected opioid overdose.
Prohibits county correction officers from dispensing medications to incarcerated individuals on the premises of a local correctional facility, but corrections officers or staff may dispense or administer medications used for the emergency treatment of known or suspected opioid overdose.
Requires facilities that provide treatment for substance use disorders to have at least one practitioner qualified to administer or prescribe buprenorphine to individuals in their care with substance use disorders related to opioids.
Requires facilities that provide treatment for substance use disorders to have at least one practitioner qualified to administer or prescribe buprenorphine to individuals in their care with substance use disorders related to opioids.
Requires mental health practitioners to receive training on substance use disorder, the specific needs of the substance use disorder community and co-occurring disorders.